Phibro Animal Health have today revealed plans to establish a new biotech facility in Sligo, creating up to 150 jobs for the North West Region.
The new facility will produce a range of innovative animal health vaccines in the IDA Ireland Finisklin Business Park in Sligo. Up to 150 jobs will be created over 5 years.
Phibro Animal Health Corporation is a publicly traded company headquartered in Teaneck, New Jersey, United States. The Sligo plant will be the company’s first biologicals manufacturing location in Europe and will allow Phibro to expand its presence in Europe. The project is supported by the Irish Government through IDA Ireland.
The new manufacturing facility will initially focus on producing Phibro’s innovative line of vaccines for the treatment of a range of poultry diseases for sales globally. In the future, Phibro expects to expand production to include vaccines for livestock and aquaculture.
Making the announcement in Sligo today, Minister for Agriculture, Food and the Marine, Michael Creed T.D, said, “This significant investment by Phibro is a great vote of confidence in Sligo, and will offer even more opportunities for local residents and communities to grow and thrive.
“It further strengthens Ireland’s Life Sciences capability in the North West and builds on a series of new IDA projects announced for Sligo and elsewhere in the region over recent times.”
Minister for Business, Enterprise & Innovation, Heather Humphreys TD, said, “I was delighted to see Phibro announce that their first biologicals manufacturing location in Europe will be in Sligo, creating up to 150 highly skilled jobs.
“This has been a fantastic few weeks for Sligo with announcements from Abtran, E3 Retail, and Live Tiles, showing how the county is benefiting from both indigenous and FDI investment. This is another example of the success of our commitment under the Regional Action Plans for Jobs to ensure we have the right conditions in place to encourage job creation in regional locations.”
Jack Bendheim, Phibro’s Chairman, President and Chief Executive Officer, commented, “The creation of Phibro Ireland marks an important milestone in our development as a leading global player in the animal health biological market.
“The winning combination of Phibro’s expertise in the development and manufacture of biological products, the driven and experienced workforce available in the Sligo area, and the strong support of the IDA makes us very excited about the potential of the Sligo facility.”
The new roles will include management, quality analysis, quality control, regulatory, engineering, operators and maintenance staff. For more information on the new roles email hr.sligo@pahc.com.
Tags: